Lumos Diagnostics (ASX:LDX) has reported encouraging real-world data from the use of its FebriDx point-of-care test across general practice, urgent care, and Acute Respiratory Infection hubs in the UK, showing the device can reduce unnecessary antibiotic use, improve patient satisfaction, and ease health system costs. …
Real-world evidence shows Lumos Diagnostics’ FebriDx cuts antibiotic use and delivers system savings
September 24, 2025 Australian Biotech
Latest Video
Georgia Forrest
New Stories
-
The Dispatched Podcast 'Week in Review' - 20 February
February 20, 2026 - - Podcast -
PhRMA launches new campaign against the backdrop of a more assertive U.S.
February 19, 2026 - - Latest News -
Why does anyone accept a review outcome that simply affirms a settled order
February 19, 2026 - - Latest News -
Wesfarmers Health emerges as growth engine after delivering strong first half
February 19, 2026 - - Australian Biotech -
Telix files for European approval of brain cancer imaging candidate TLX101-Px
February 18, 2026 - - Australian Biotech -
IDT signals turnaround as revenue rises and losses narrow under strategic reset
February 18, 2026 - - Latest News -
Nyrada advances lead candidate into mid-stage trial as momentum builds across programs
February 18, 2026 - - Australian Biotech